Abstract
Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Current Drug Therapy
Title: Incretin-Based Therapies in Patients with Type 2 Diabetes
Volume: 5 Issue: 2
Author(s): Jeffrey S. Freeman, DO
Affiliation:
Keywords: Drug therapy, exenatide, GLP-1 receptor agonists, glycemic control, incretins, obesity, type 2 diabetes mellitus
Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent and progressive metabolic disease associated with significant morbidity and mortality. While glycemic control remains the cornerstone of disease treatment, successful T2DM management requires consideration of several comorbid risk factors including overweight/obesity, dyslipidemia, and hypertension. Early and aggressive treatment of patients with T2DM should be implemented to slow disease progression and prevent long-term complications. This necessitates the selection of antidiabetes agents that effectively lower hyperglycemia and target the other fundamental defects of T2DM. Treatment regimens should be individualized according to patient profiles and risk factors. This is especially germane for overweight/obese patients with T2DM, who have an even higher risk for complications. Several newer antidiabetes agents, in particular, incretin-based therapies, target the underlying defects of T2DM, provide glycemic control with beneficial effects on cardiovascular risk factors including lipids and blood pressure while avoiding weight gain. These represent important therapeutic options for the management of patients with T2DM.
Export Options
About this article
Cite this article as:
S. Freeman, DO Jeffrey, Incretin-Based Therapies in Patients with Type 2 Diabetes, Current Drug Therapy 2010; 5 (2) . https://dx.doi.org/10.2174/157488510791065094
DOI https://dx.doi.org/10.2174/157488510791065094 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Emerging Nanocarriers-based Approaches to Diagnose and Red uce Vascular Inflammation in Atherosclerosis
Current Medicinal Chemistry Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews Editorial (Thematic Issue: New Technological and Clinical Trends in Blood Pressure Theranostics: Is it Time to Consider a Spatio-Temporal Approach?)
Current Pharmaceutical Design Clinical Experience with Specific COX-2 Inhibitors in Arthritis
Current Pharmaceutical Design Toll-like Receptor as a Molecular Link between Metabolic Syndrome and Inflammation: A Review
Current Drug Targets Hydrolyzates of Silkworm Pupae (Bombyx Mori) Protein is a New Source of Angiotensin I-Converting Enzyme Inhibitory Peptides(ACEIP)
Current Pharmaceutical Biotechnology Postpartum Depression in Women with the FMR1 Premutation
Current Psychiatry Reviews Novel Mutation of the NOTCH3 Gene in a Chinese Pedigree with CADASIL
CNS & Neurological Disorders - Drug Targets Disease Outcome, Alexithymia and Depression are Differently Associated with Serum IL-18 Levels in Acute Stroke
Current Neurovascular Research Pharmacological and Cellular Therapies to Prevent Restenosis after Percutaneous Transluminal Angioplasty and Stenting
Cardiovascular & Hematological Agents in Medicinal Chemistry The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma
Current Pharmaceutical Biotechnology Polypeptide Toxins from Animal Venoms
Recent Patents on DNA & Gene Sequences Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) Beneficial Morphofunctional Changes Promoted by Sildenafil in Resistance Vessels in the Angiotensin II-Induced Hypertension Model
Current Pharmaceutical Biotechnology Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Pyrazolines: A Biological Review
Mini-Reviews in Medicinal Chemistry Liver-Related Factors Associated with Low Vitamin D Levels in HIV and HIV/HCV Coinfected Patients and Comparison to General Population
Current HIV Research An Efficient One-Pot Organocatalyzed Synthesis of Spiro[Chroman-3,6'- Furo[2,3-d]Pyrimidine]-Tetraones
Combinatorial Chemistry & High Throughput Screening